Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination

Inclusion Criteria: * Non-hysterectomised postmenopausal women * Amenorrhoea for \>= 12 months * Serum estradiol and follicle stimulating hormone (FSH) in the postmenopausal range Exclusion Criteria: * Known hypersensitivity to estradiol, dydrogesterone or any of the excipients of the study medication * Baseline endometrial biopsy result other than described in the inclusion criteria (no endometrial tissue for diagnosis, hyperplasia, carcinoma). * Insufficient endometrial tissue for diagnosis obtained at baseline biopsy and endometrial thickness \>= 5 mm (double layer) by transvaginal ultrasound. * The presence of an endometrial polyp at baseline. * Abnormal (un-investigated and/or unexplained) vaginal bleeding in the last 12 months prior to Screening Visit (Visit 1). * Estradiol pellet/implant therapy during the past 6 months. * Previous systemic unopposed estrogen replacement therapy over 6 months or more. * History or presence of malignant neoplasms other than basal or spinal cell carcinoma of the skin